Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme- Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.585
https://www.valueinhealthjournal.com/article/S1098-3015(13)02490-X/fulltext
Title :
Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme- Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02490-X&doi=10.1016/j.jval.2013.08.585
First page :
A425
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
565